EZN 2968

11/01/2008 - "Ongoing phase I studies of EZN-2968 in patients with advanced malignancies will determine optimal dose and schedule for the phase II program."
11/01/2008 - "In efficacy studies, tumor reduction was found in nude mice implanted with DU145 cells treated with EZN-2968. "
02/01/2014 - "Adult patients with refractory advanced solid tumors were administered EZN-2968 as a 2-h IV infusion at a dose of 18 mg/kg once a week for three consecutive weeks followed by 3-week off; in a 6-week cycle. "
02/01/2014 - "Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1α), in patients with refractory solid tumors."
11/01/2008 - "A RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth."

02/01/2014 - "Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1α), in patients with refractory solid tumors."
11/01/2008 - "A RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth."

11/01/2008 - "In vitro, in human prostate (15PC3, PC3, and DU145) and glioblastoma (U373) cells, EZN-2968 induced a potent, selective, and durable antagonism of HIF-1 mRNA and protein expression (IC(50), 1-5 nmol/L) under normoxic and hypoxic conditions associated with inhibition of tumor cell growth. "